ArticleBMC psychiatry2024

Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.

A R Müller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.